Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart cafraglutide in obesity
NCT04478708Phase 1Completed
- Sponsor
- Amgen
- Start
- Aug 2020
- Primary completion
- Nov 2022
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of maridebart cafraglutide in obesity (5 arms), sponsored by Amgen. Primary endpoint: Treatment-emergent Adverse Events. Started Aug 2020; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04478708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478708.